Cellectis (NASDAQ:CLLS) Posts Earnings Results, Beats Estimates By $0.08 EPS

Cellectis (NASDAQ:CLLS) issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.08, Zacks reports. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million.

Cellectis Price Performance

Shares of CLLS traded up $0.38 during trading hours on Thursday, hitting $3.31. The stock had a trading volume of 27,298 shares, compared to its average volume of 41,888. The stock has a market capitalization of $332.62 million, a price-to-earnings ratio of -4.94 and a beta of 2.86. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. Cellectis has a 52 week low of $1.56 and a 52 week high of $5.48. The company’s fifty day moving average is $3.45 and its two-hundred day moving average is $3.78.

Analyst Upgrades and Downgrades

CLLS has been the topic of a number of research analyst reports. Barclays began coverage on shares of Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target on the stock. Citizens Jmp reiterated a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cellectis currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP lifted its stake in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Cellectis in the fourth quarter valued at approximately $15,385,000. Global Retirement Partners LLC bought a new position in Cellectis during the fourth quarter worth $34,000. Millennium Management LLC grew its stake in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Cellectis during the third quarter worth approximately $633,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.